{
    "title": "112_s1700",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medical Device Regulatory \nImprovement Act''.\n\nSEC. 2. CLARIFICATION OF LEAST BURDENSOME.\n\n    (a) Premarket Approval.--Section 513(a)(3)(D) of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 360c(a)(3)(D)) is amended--\n            (1) by redesignating clause (iii) as clause (iv); and\n            (2) by inserting after clause (ii) the following:\n    ``(iii) In carrying out clause (ii), the Secretary--\n            ``(I) shall not request information unrelated or irrelevant \n        to a demonstration of reasonable assurance of device safety and \n        effectiveness;\n            ``(II) shall consider alternative approaches to evaluating \n        device safety and effectiveness in order to reduce the time, \n        effort, and cost of reaching proper resolution of the issue;\n            ``(III) shall use all reasonable mechanisms to lessen \n        review times and render regulatory decisions;\n            ``(IV) shall determine whether pre-clinical data, such as \n        well-designed bench and animal testing, can meet the statutory \n        threshold for approval; and\n            ``(V) if clinical data are needed, shall utilize, whenever \n        practicable, alternatives to randomized, controlled clinical \n        trials, such as the use of surrogate endpoints.''.\n    (b) Substantial Equivalence Determination.--Section 513(i)(1)(D) of \nthe Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360c(i)(1)(D)) is \namended--\n            (1) by striking ``(D) Whenever'' and inserting ``(D)(i) \n        Whenever''; and\n            (2) by adding at the end the following:\n    ``(ii) In carrying out clause (i), the Secretary--\n            ``(I) shall focus on whether the device has the same \n        intended use as the predicate device and is as safe and \n        effective as a legally marketed device;\n            ``(II) shall not request or accept information unrelated or \n        irrelevant to the substantial equivalence evaluation;\n            ``(III) shall review the labeling of the device to assess \n        the intended use of the device, and shall not evaluate issues \n        that do not present a major impact on the intended use as set \n        forth in the labeling;\n            ``(IV) shall consider alternative approaches to evaluating \n        substantial equivalence in order to reduce the time, effort, \n        and cost of reaching proper resolution of the issue; and\n            ``(V) shall use all reasonable mechanisms to lessen review \n        times and render regulatory decisions.''.\n\nSEC. 3. CONFLICTS OF INTEREST.\n\n    Section 712 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n379d-1) is amended to read as follows:\n\n``SEC. 712. CONFLICTS OF INTEREST.\n\n    ``Except as otherwise provided in this Act, each advisory committee \nunder the Federal Advisory Committee Act that provides advice or \nrecommendations to the Secretary regarding activities of the Food and \nDrug Administration is subject to the provisions in such Act and the \nmembers of each such committee are subject to the provisions regarding \nFederal employees and special Government employees, as applicable, in \ntitle I of the Ethics in Government Act of 1978 and section 208 of \ntitle 18, United States Code.''.\n\nSEC. 4. MANAGEMENT AND INNOVATION REVIEW.\n\n    (a) In General.--Not later than 60 days after the date of enactment \nof this Act, the Secretary of Health and Human Services (referred to in \nthis section as the ``Secretary'') shall enter into a contract with an \neligible entity to carry out the activities described in subsection \n(c).\n    (b) Eligible Entity.--To be eligible to enter into a contract with \nthe Secretary under subsection (a), an entity shall--\n            (1) be an entity with experience in evaluating the \n        management and operating structure of large organizations; and\n            (2) submit to the Secretary an application at such time, in \n        such manner, and containing such information as the Secretary \n        may require.\n    (c) Activities.--The entity with which the Secretary enters into \nthe contract under subsection (a) shall, pursuant to such contract, \nconduct an extensive review of the management and regulatory processes \nat the Center for Devices and Radiological Health of the Food and Drug \nAdministration to ensure any actions carried out by such Center take \ninto consideration the potential impacts on innovation with respect to \nmedical devices and other products regulated by such Center.\n    (d) Report.--Not later than 1 year after the date that the \nSecretary enters into the contract with the eligible entity under \nsubsection (a), such entity shall submit to Congress and the Secretary \na report that describes the findings and recommendations of such entity \nbased on the review conducted under subsection (c).\n    (e) Funding.--To carry out this section, the Secretary shall use \nfunds otherwise available for the operation of the Office of the \nSecretary."
}